North America Opioid Use Disorder Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

North America Opioid Use Disorder Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Country Analysis

North America Opioid Use Disorder Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
North America Opioid Use Disorder Totalxxxxxxxxxxxx9.2%
United Statesxxxxxxxxxxxx9%
Canadaxxxxxxxxxxxx10%
Mexicoxxxxxxxxxxxx9.7%

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Drug Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.

Buprenorphine North America Opioid Use Disorder Market Analysis
XX
Buprenorphine Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Naltrexone North America Opioid Use Disorder Market Analysis
XX
Naltrexone Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Methadone North America Opioid Use Disorder Market Analysis
XX
Methadone Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the Opioid Use Disorder Market

The market for opioid use disorders (OUDs) is very competitive, with major manufacturers like Pfizer, Mallinckrodt, Alkermes, and Indivior holding a monopoly on well-known medication-assisted therapies (MATs) like naltrexone and buprenorphine. Innovative medicines and digital health solutions are the main focus of emerging firms. As the need for efficient OUD management options grows, competition is fueled by developments in treatment efficacy, regulatory approvals, and access expansion initiatives.

March 2023: The goal of Indivior PLC's acquisition of Opiant Pharmaceuticals, Inc. was to enhance the care of patients suffering from overdose or opioid addiction. With this acquisition, the company's position in the market was expected to increase. (Source:https://www.indivior.com/en/media/press-releases/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc) February 2023: The U.S. FDA has received a new drug application (NDA) for Orexo AB's primary pharmaceutical pipeline candidate, OX124, a nasal rescue drug for opioid overdose. (Source:https://orexo.com/news-room/pressreleases-and-news/2023-02-03-orexo-submits-new-drug-application-to-fda-for-ox124-a-high-dose-rescue-medication-for-opioid-overdose) February 2021: ApexB.io, Magellan Rx Management, and Orexo AB worked together to research the application of Modia. Patients with opioid use disorder can benefit from a digital therapy called Modia. (Source:https://orexo.com/news-room/pressreleases-and-news/2021-02-10-orexo-starts-to-test-modia-on-patients-in-collaboration-with-apexb-io-and-magellan-rx-management) June 2020: Titan Pharmaceuticals, Inc. and Indegene have announced plans to expand their capacity to provide Buprenorphine implants for opioid-addicted patients and launch a multichannel digital marketing initiative in the United States. (Source:https://www.titanpharm.com/news/press-releases/detail/238/titan-pharmaceuticals-and-indegene-enter-into-probuphine-co-promotion-partnership)
Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Company 1••• ••• ••• •••
Company 2••• ••• ••• •••
Company 3••• ••• ••• •••
Company 4••• ••• ••• •••
Company 5••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global Opioid Use Disorder market size was estimated at USD 2965.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1186.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.

  • According to Cognitive Market Research, the US had a major share in the Opioid Use Disorder market with a market size of USD 935.82 million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. Due to the severe opioid crisis and high rates of addiction in the country, there is a growing need for all-encompassing treatment solutions.
  • The Canada Opioid Use Disorder market had a market share of USD 142.33 million in 2024 and is projected to grow at a CAGR of 10.0% during the forecast period. The market is driven by Canada's funding and supportive policies for addiction treatment, which include supervised consumption facilities.
  • The Mexico Opioid Use Disorder market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 107.93 million in 2024.
The ongoing opioid crisis in North America has resulted in a major increase in the demand for Opioid Use Disorder (OUD) treatment in hospitals and clinics. Comprehensive care, which includes integrated behavioral health treatments, emergency interventions, and medication-assisted therapy (MAT), is largely provided by hospitals and clinics. The necessity for specialized treatment facilities and programs within various healthcare settings has been spurred by the prevalence of opioid addiction, especially in the United States and Canada. The expansion of OUD services in hospitals and clinics is also being supported by more government funding, regulatory assistance, and awareness campaigns. This increasing demand highlights how important these institutions are to combating the opioid crisis in North America.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The North America Opioid Use Disorder Market Analysis is witnessing significant growth in the near future.

In 2023, the Buprenorphine segment accounted for a notable share of the North America Opioid Use Disorder Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst at Cognitive Market Research
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

North America Opioid Use Disorder Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers and others are profiled in the report.
Segments include Drug Type, Age Group and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

North America Opioid Use Disorder Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Drug TypeBuprenorphine, Naltrexone, Methadone
Age Group19 to 39, 40 to 59, Aged 60 and over
Route of AdministrationOral, Intravenous
Distribution ChannelHospital Pharmacy, Retail Pharmacy
List of CompetitorsIndivior PLC, Titan Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Hikma Pharmaceuticals PLC, Viatris Inc. (Mylan N.V.), Alkermes, Orexo AB, Camurus

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Top Players Ranking 2024
      • 1.1.2 New Product Launch Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Indivior PLC
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 R&D Investment (Subject to data availability)
        • 1.2.1.4 Financials (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Titan Pharmaceuticals
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 R&D Investment (Subject to data availability)
        • 1.2.2.4 Financials (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Inc.
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 R&D Investment (Subject to data availability)
        • 1.2.3.4 Financials (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Mallinckrodt Pharmaceuticals
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 R&D Investment (Subject to data availability)
        • 1.2.4.4 Financials (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 BioDelivery Sciences International Inc.
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 R&D Investment (Subject to data availability)
        • 1.2.5.4 Financials (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Hikma Pharmaceuticals PLC
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 R&D Investment (Subject to data availability)
        • 1.2.6.4 Financials (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Viatris Inc. (Mylan N.V.)
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 R&D Investment (Subject to data availability)
        • 1.2.7.4 Financials (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Alkermes
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 R&D Investment (Subject to data availability)
        • 1.2.8.4 Financials (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Orexo AB
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 R&D Investment (Subject to data availability)
        • 1.2.9.4 Financials (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Camurus
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 R&D Investment (Subject to data availability)
        • 1.2.10.4 Financials (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis

  • Chapter 2. Global Opioid Use Disorder Market Analysis

    • 2.1 Global Opioid Use Disorder Market Analysis
    • 2.2 Global Opioid Use Disorder Market Analysis by Drug Type
    • 2.3 Global Opioid Use Disorder Market Analysis by Age Group
    • 2.4 Global Opioid Use Disorder Market Analysis by Route of Administration
    • 2.5 Global Opioid Use Disorder Market Analysis by Distribution Channel

  • Chapter 3. North America Opioid Use Disorder Market Analysis

    • 3.1 North America Opioid Use Disorder Market Analysis
    • 3.2 North America Opioid Use Disorder Market Analysis by Country
    • 3.3 North America Opioid Use Disorder Market Analysis by Drug Type
    • 3.4 North America Opioid Use Disorder Market Analysis by Age Group
    • 3.5 North America Opioid Use Disorder Market Analysis by Route of Administration
    • 3.6 North America Opioid Use Disorder Market Analysis by Distribution Channel
    • 3.7 North America Opioid Use Disorder Market Analysis by Key Players

  • Chapter 4. United States Opioid Use Disorder Market Analysis

    • 4.1 United States Opioid Use Disorder Market Analysis
    • 4.2 United States Opioid Use Disorder Market Analysis by Drug Type
    • 4.3 United States Opioid Use Disorder Market Analysis by Age Group
    • 4.4 United States Opioid Use Disorder Market Analysis by Route of Administration
    • 4.5 United States Opioid Use Disorder Market Analysis by Distribution Channel
    • 4.6 United States Opioid Use Disorder Market Analysis by Key Players

  • Chapter 5. Canada Opioid Use Disorder Market Analysis

    • 5.1 Canada Opioid Use Disorder Market Analysis
    • 5.2 Canada Opioid Use Disorder Market Analysis by Drug Type
    • 5.3 Canada Opioid Use Disorder Market Analysis by Age Group
    • 5.4 Canada Opioid Use Disorder Market Analysis by Route of Administration
    • 5.5 Canada Opioid Use Disorder Market Analysis by Distribution Channel
    • 5.6 Canada Opioid Use Disorder Market Analysis by Key Players

  • Chapter 6. Mexico Opioid Use Disorder Market Analysis

    • 6.1 Mexico Opioid Use Disorder Market Analysis
    • 6.2 Mexico Opioid Use Disorder Market Analysis by Drug Type
    • 6.3 Mexico Opioid Use Disorder Market Analysis by Age Group
    • 6.4 Mexico Opioid Use Disorder Market Analysis by Route of Administration
    • 6.5 Mexico Opioid Use Disorder Market Analysis by Distribution Channel
    • 6.6 Mexico Opioid Use Disorder Market Analysis by Key Players

  • Chapter 7. Drug Type Analysis

    • 7.1 Buprenorphine
    • 7.2 Naltrexone
    • 7.3 Methadone

  • Chapter 8. Age Group Analysis

    • 8.1 19 to 39
    • 8.2 40 to 59
    • 8.3 Aged 60 and over

  • Chapter 9. Route of Administration Analysis

    • 9.1 Oral
    • 9.2 Intravenous

  • Chapter 10. Distribution Channel Analysis

    • 10.1 Hospital Pharmacy
    • 10.2 Retail Pharmacy

  • Chapter 11. Qualitative Analysis (Subject to Data Availability)

    • 11.1 Market Drivers
    • 11.2 Market Restraints
    • 11.3 Market Trends
    • 11.4 Market Opportunity
    • 11.5 Technological Road Map (Subject to Data Availability)
    • 11.6 Product Life Cycle (Subject to Data Availability)
    • 11.7 Customer and Buyer Behavior Analysis
      • 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 11.7.4 Pricing, Affordability & Value Perception Analysis
      • 11.7.5 Customer Segmentation & Demand Pattern Analysis
    • 11.8 Industrial Chain Analysis (Subject to Data Availability)
      • 11.8.1 Industry Chain Analysis
      • 11.8.2 Manufacturing Cost Analysis
      • 11.8.3 Supply Side Analysis
        • 11.8.3.1 Raw Material Analysis
        • 11.8.3.2 Raw Material Procurement Analysis
        • 11.8.3.3 Raw Material Price Trend Analysis
    • 11.9 PESTEL Analysis
      • 11.9.1 Environmental Factors
      • 11.9.2 Legal Factors
      • 11.9.3 Technological Factors
      • 11.9.4 Economic Factors
      • 11.9.5 Political Factors
      • 11.9.6 Social Factors
    • 11.10 Porter’s Five Forces Analysis
      • 11.10.1 Degree of Competition
      • 11.10.2 Threat of Substitutes
      • 11.10.3 Threat of New Entrants
      • 11.10.4 Bargaining Power of Buyers
      • 11.10.5 Bargaining Power of Suppliers
    • 11.11 Patent Analysis (Subject to Data Availability)
    • 11.12 ESG Analysis
    • 11.13 Geopolitical Outlook
      • 11.13.1 Global Power Realignment & Strategic Alliances
      • 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 11.13.3 International Trade Relations & Market Access Environment
      • 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 11.13.6 Technology Sovereignty & Digital Geopolitics
      • 11.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 11.14 AI & Market Transformation
      • 11.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 11.14.2 AI-Driven Transformation of Industry Value Chain
      • 11.14.3 Evolution of Business Models & Revenue Streams
      • 11.14.4 AI-Driven Product, Service & Innovation Transformation
      • 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 12. Research Findings

    • 12.1 Key Takeaways
    • 12.2 Analyst Point of View
    • 12.3 Assumptions and Acronyms

  • Chapter 13. Research Methodology and Sources

    • 13.1 Primary Data Collection
      • 13.1.1 Steps for Primary Data Collection
        • 13.1.1.1 Identification of KOL
      • 13.1.2 Backward Integration
      • 13.1.3 Forward Integration
      • 13.1.4 How Primary Research Help Us
      • 13.1.5 Modes of Primary Research
    • 13.2 Secondary Research
      • 13.2.1 How Secondary Research Help Us
      • 13.2.2 Sources of Secondary Research
    • 13.3 Data Validation
      • 13.3.1 Data Triangulation
    • 13.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the North America Opioid Use Disorder Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 22+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Medical Devices and Consumables Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the North America Opioid Use Disorder Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the north america opioid use disorder market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.